FAIRBAIRN EMILY 4

What Happened

• Emily Fairbairn, a director of IN8BIO, was granted a derivative award (reported as an option) covering 22,000 shares on 2026-05-09. The transaction is reported as an acquisition at $0.00 (derivative instrument).

Key Details

• Transaction date: 2026-05-09; Form 4 filed: 2026-05-12 (three calendar days later).
• Instrument: Derivative award (described in the filing as an option) for 22,000 shares, reported at $0.00.
• Vesting: Per footnote, one-twelfth of the option vests in equal monthly installments beginning June 9, 2026; the option will be fully vested on the date of the company’s next annual meeting of stockholders, provided Fairbairn continues to provide service.
• Shares owned after transaction: Not specified in the provided filing details.
• No sale or immediate cashless exercise was reported.

Context

• This was a grant (award) rather than a market purchase or sale. Grants are routine for compensation and do not by themselves indicate buying or selling sentiment. Because this is a derivative (an option award), the economic benefit depends on future vesting and any exercise terms. Check subsequent filings for exercises, sales, or additional disclosure.